H.I.G. BioHealth Partners

H.I.G. BioVentures invests in a broad range of life science companies across multiple sectors and stages of development. Their seasoned investment team has extensive and diverse experience in big pharma, small biotech, medical devices, diagnostics, basic science, clinical research, and technology transfer. They invest in companies developing novel products for significant unmet medical needs.

Navneet Alag

Principal

Tiffany Chen

Vice President

Quentin Langlois

Vice President

Bruce Robertson

Managing Director

Michael Wasserman

Managing Director

Gwen Watanabe

Managing Director

Alex Zisson

Managing Director

26 past transactions

Intact Vascular

Series B in 2017
Intact Vascular, Inc., a medical device company, develops medical devices for minimally invasive peripheral vascular procedures. The company offers Tack Endovascular System, a device that offers optimization of peripheral balloon angioplasty results during the treatment of peripheral arterial disease (PAD) and critical limb ischemia (CLI). Intact Vascular, Inc. was formerly known as Tackit Vascular LLC. The company was founded in 2011 and is based in Wayne, Pennsylvania.

Exagen

Venture Round in 2019
Exagen is a patient focused, discovery-driven life science company that addresses the unmet need for the accurate diagnosis and monitors patients affected by autoimmune rheumatic diseases. The company also provides AVISE tests that are specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis, and better disease management. Exagen was established in 2002 and is headquartered in Vista, California.

Arvelle Therapeutics

Series A in 2019
Arvelle Therapeutics GmbH, a biopharmaceutical company, focuses on solutions for patients suffering from CNS disorders. It is involved in the development and commercialization of cenobamate, an investigational antiepileptic drug in the European market. The company was founded in 2019 and is headquartered in Zug, Switzerland.

Intact Vascular

Series B in 2015
Intact Vascular, Inc., a medical device company, develops medical devices for minimally invasive peripheral vascular procedures. The company offers Tack Endovascular System, a device that offers optimization of peripheral balloon angioplasty results during the treatment of peripheral arterial disease (PAD) and critical limb ischemia (CLI). Intact Vascular, Inc. was formerly known as Tackit Vascular LLC. The company was founded in 2011 and is based in Wayne, Pennsylvania.

Zerigo Health

Series A in 2019
Clarify Medical, Inc. develops home therapy solutions for chronic skin treatments. It offers The Clarify mobile ultra violet B treatment system, an investigational device for use in treating plaque psoriasis, eczema, and vitiligo; and Home Light Therapy System, a home phototherapy system for the treatment of psoriasis, vitiligo, and eczema. Clarify Medical, Inc. was formerly known as Skylit Medical, Inc. and changed its name to Clarify Medical, Inc. in September 2016. The company was incorporated in 2014 and is based in San Diego, California.

RxSight

Debt Financing in 2015
RxSight is a medical device company that offers an intraocular lens and cataract surgery solutions. Using a proprietary light treatment that produces precise modifications in lens curvature, RxSight’s Light Adjustable Lens (RxLAL) enables doctors and patients to predictably optimize vision after cataract surgery through an office-based IOL enhancement. The company’s mission is to revolutionize the premium cataract surgery experience by allowing surgeons to partner with their patients to achieve optimized results for every unique eye. It was founded in 1997 and is headquartered in Aliso Viejo, California, United States.

Intact Vascular

Series D in 2019
Intact Vascular, Inc., a medical device company, develops medical devices for minimally invasive peripheral vascular procedures. The company offers Tack Endovascular System, a device that offers optimization of peripheral balloon angioplasty results during the treatment of peripheral arterial disease (PAD) and critical limb ischemia (CLI). Intact Vascular, Inc. was formerly known as Tackit Vascular LLC. The company was founded in 2011 and is based in Wayne, Pennsylvania.

RxSight

Venture Round in 2015
RxSight is a medical device company that offers an intraocular lens and cataract surgery solutions. Using a proprietary light treatment that produces precise modifications in lens curvature, RxSight’s Light Adjustable Lens (RxLAL) enables doctors and patients to predictably optimize vision after cataract surgery through an office-based IOL enhancement. The company’s mission is to revolutionize the premium cataract surgery experience by allowing surgeons to partner with their patients to achieve optimized results for every unique eye. It was founded in 1997 and is headquartered in Aliso Viejo, California, United States.

Neurana Pharmaceuticals

Series A in 2018
Neurana Pharmaceuticals, Inc. is a pharmaceutical company that develops treatment for neuromuscular conditions, including acute and painful muscle spasms of the neck and back. The company provides Tolperisone, a therapeutic compound that treats musculoskeletal conditions, including neuromuscular spasms and spasticity without sedation. The company was formerly known as Katama Pharmaceuticals Inc. Neurana Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in San Diego, California.

Orbus Therapeutics

Series A in 2015
They at Orbus are committed to bringing innovative products to the extremely underserved patients affected by rare diseases. They are focused and passionate about bringing a more positive outcome to patients facing life-threatening or significantly life-altering diseases. Currently, Orbus Therapeutics is working to develop and commercialize eflornithine in North America. The company was founded in 2012 and is headquartered in Palo Alto, California.

On Target Laboratories

Series B in 2018
On Target Laboratories, LLC engages in discovering, developing, and commercializing small molecules that target specific pathological cells, when conjugated with fluorescent dyes. It offers folate and other targeting agents that target, lung, uterine, kidney, breast, colon, pancreatic, and prostate cancer cells. The company was incorporated in 2010 and is based in Northbrook, Illinois.

Iconic Therapeutics

Series C in 2016
Iconic Therapeutics, Inc. operates as a biopharmaceutical company that translates tissue factor biology in angiogenesis, inflammation, and metastasis to develop new therapeutics for retinal disease and cancer. Its products include ICON-1, a fusion protein designed to address the basis of vision loss in age-related macular degeneration. Iconic Therapeutics, Inc. was incorporated in 2002 and is based in South San Francisco, California.

ForSight Labs

Series C in 2014
ForSight Labs is focused on developing and applying solutions to improve the sight, care, and quality of life of visually impaired patients. Our environment is creative and collaborative; a place where entrepreneurs and investors work together to drive innovative technologies through concept, development, and ultimately commercialization in high-impact eye care companies (ForSight VISION companies). Each day millions of people rely on their vision and suffer when it is lost. There are few disabilities as impactful to quality of life as the loss of vision. The number of people with impaired vision in the US, including blindness, is expected to more than double over the next three decades. Recent estimates of the cost of vision loss in the US exceed $50 billion dollars annually. ForSight Labs brings together highly motivated and capable team members, clinicians and investors focused on starting and sustaining efforts to deliver innovative solutions to the ophthalmic community and the patients it serves.

Intact Vascular

Series A in 2012
Intact Vascular, Inc., a medical device company, develops medical devices for minimally invasive peripheral vascular procedures. The company offers Tack Endovascular System, a device that offers optimization of peripheral balloon angioplasty results during the treatment of peripheral arterial disease (PAD) and critical limb ischemia (CLI). Intact Vascular, Inc. was formerly known as Tackit Vascular LLC. The company was founded in 2011 and is based in Wayne, Pennsylvania.

Nutrinia

Series D in 2016
Nutrinia is a neonatology company developing pharmaceuticals to treat rare conditions of the gastrointestinal tract. Our current products in development are oral formulations of insulin shown to enhance adaptation and rehabilitation of the gut in infants. We at Nutrinia live by the belief that science is best used to make life better for people, especially the most vulnerable populations.

Iconic Therapeutics

Venture Round in 2018
Iconic Therapeutics, Inc. operates as a biopharmaceutical company that translates tissue factor biology in angiogenesis, inflammation, and metastasis to develop new therapeutics for retinal disease and cancer. Its products include ICON-1, a fusion protein designed to address the basis of vision loss in age-related macular degeneration. Iconic Therapeutics, Inc. was incorporated in 2002 and is based in South San Francisco, California.

Click Therapeutics

Series B in 2021
Click Therapeutics, Inc. engineers, validates, develops, and commercializes digital therapeutics solutions to benefit people with unmet medical needs through cognitive and neurobehavioral modification. It develops and commercializes novel digital therapeutics for various indications, including smoking cessation, major depressive disorders, schizophrenia, insomnia, acute coronary syndrome, migraine, overactive bladder, chronic low back pain, and obesity. Click Therapeutics, Inc. was founded in 2012 and is based in New York, New York.

NeuWave Medical

Series B in 2012
NeuWave Medical develops tools that deliver energy to the human body to treat a variety of serious medical conditions. Their company founders are both engineers and physician-scientists which allows determining a clinical need and design solutions that are clinically relevant, effective, and minimally invasive. They strive to make the highest quality devices that are the products of choice for leading physicians and medical centers around the world. The company was founded in 2004 and is headquartered in Madison, Wisconsin.

Cerephex

Series A in 2012
Cerephex is a company developing its proprietary RINCE technology for treatment applications involving noninvasive brain stimulation. Cerephex is currently engaged in development activities aimed at gaining FDA approval of its NeuroPoint device for the management of fibromyalgia, a chronic pain condition that involves abnormal central pain processing mechanisms.

Iconic Therapeutics

Series B in 2014
Iconic Therapeutics, Inc. operates as a biopharmaceutical company that translates tissue factor biology in angiogenesis, inflammation, and metastasis to develop new therapeutics for retinal disease and cancer. Its products include ICON-1, a fusion protein designed to address the basis of vision loss in age-related macular degeneration. Iconic Therapeutics, Inc. was incorporated in 2002 and is based in South San Francisco, California.

ForSight VISION5

Series C in 2014
ForSight VISION5 was founded in 2010 as the fifth company created by the ophthalmic product incubator, ForSight Labs. ForSight VISION5 is developing non-invasive products that replace eye drops and provide sustained therapy for major eye diseases including glaucoma, dry eye, and allergy. The company is currently in its second Phase 2 clinical study for its lead product, the Helios insert.

NeuWave Medical

Series C in 2015
NeuWave Medical develops tools that deliver energy to the human body to treat a variety of serious medical conditions. Their company founders are both engineers and physician-scientists which allows determining a clinical need and design solutions that are clinically relevant, effective, and minimally invasive. They strive to make the highest quality devices that are the products of choice for leading physicians and medical centers around the world. The company was founded in 2004 and is headquartered in Madison, Wisconsin.

Cardeas Pharma

Series B in 2015
Cardeas Pharma is developing a novel antibiotic formulation of two drugs with synergistic activity against all relevant, highly resistant Gram-negative bacilli, including Pseudomonas aeruginosa, Acinetobacter baumannii, and carbapenem-resistant Enterobacteriaceae. In addition, this antibiotic formulation has activity on biofilms. The combination also has activity against Gram-positive pathogens including methicillin-resistant Staphylococcus aureus (MRSA). This formulation is administered using a single-patient use, vibrating-plate nebulizer that is compatible with all ventilators. The nebulizer creates small, uniform aerosol droplets that deliver drug to the small airways and alveoli. Integration of this novel antibiotic formulation and device has the potential to achieve significant clinical outcomes relative to current standard therapy.

VertiFlex

Venture Round in 2017
VertiFlex, Inc., a medical device company, provides minimally invasive and motion preserving spinal surgery technologies in the United States and internationally. The company offers superion interspinous spacer, a percutaneous titanium implant that fits between the spinous processes in the lumbar spine. Its Superion is a motion-preserving interspinous spacer for the treatment of moderate spinal stenosis. Vertiflex Inc was founded in 2005 and is headquartered in California, USA.

Intact Vascular

Series C in 2018
Intact Vascular, Inc., a medical device company, develops medical devices for minimally invasive peripheral vascular procedures. The company offers Tack Endovascular System, a device that offers optimization of peripheral balloon angioplasty results during the treatment of peripheral arterial disease (PAD) and critical limb ischemia (CLI). Intact Vascular, Inc. was formerly known as Tackit Vascular LLC. The company was founded in 2011 and is based in Wayne, Pennsylvania.

Arvelle Therapeutics

Series A in 2020
Arvelle Therapeutics GmbH, a biopharmaceutical company, focuses on solutions for patients suffering from CNS disorders. It is involved in the development and commercialization of cenobamate, an investigational antiepileptic drug in the European market. The company was founded in 2019 and is headquartered in Zug, Switzerland.